GlassScriptPhysician profile
Randi S Goldstein
NPI 1679100119
$4,448.94
in general payments reported to CMS, 2019-2025
22 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.14 · 2022: $154 · 2023: $1,005 · 2024: $1,684 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,034 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,033.99 |
| Education | $181.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $923.96 | 2023-2025 | |
| Abbvie INC. | $750.10 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $431.72 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $406.68 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $207.72 | 2023-2025 | Twyneo, Aklief, Nemluvio |
| Ucb, INC. | $195.65 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $161.33 | 2025 | Zoryve |
| Leo Pharma INC. | $153.11 | 2024-2025 | Adbry |
| Janssen Scientific Affairs, LLC | $131.36 | 2024 | Tremfya |
| Lilly USA, LLC | $124.93 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $123.56 | 2023-2025 | Sotyktu |
| Amgen INC. | $102.77 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $96.88 | 2023-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $81.77 | 2024-2025 | |
| Pfizer INC. | $81.15 | 2022-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $74.14 | 2023-2024 | Vtama |
| Botanix Sb INC | $72.63 | 2025 | Sofdra |
| Revance Therapeutics, INC. | $40.91 | 2025 | Daxxify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2023 | Spevigo |
| Novartis Pharmaceuticals Corporation | $25.03 | 2025 | |
| Sun Pharmaceutical Industries INC. | $16.34 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.96 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randi Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.